The CDK4/6 inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway plays a crucial role in cell cycle progression, and its dysregulation is an important contributor to endocrine therapy resistance in breast cancer [11]. This evidence concerns the gene CDK4 and breast cancer.